

MARKET REPORT



Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022

Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer. The global Chemotherapy-induced Nausea and Vomiting market was valued at \$1,663 million in 2015, and is estimated to reach \$2,659 million by 2022, registering a CAGR of 7.1% during the forecast period. At present, pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung and bronchus cancer as most common along all the types in addition to existing number of cancer patients. The global CINV market is segmented into patient pool type and geography. The patient pool type is segmented into namely Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC and Others. Among the segments, the Netupitant Palonosetron market is expected to witness the fastest growth, globally during the forecast period 2016-2022. Based on geography, the global CINV market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share (nearly half) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy, introduction of novel delivery methods to improve patient compliance. However, Asian region is expected to grow at a fastest CAGR during the forecast period, owing to large CINV patient pool and huge demand for the Netupitant-Palonosetron from these patients. Netupitant - Palonosetron is one of the first forms of fixed dose combination, which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future.

KEY BENEFITS

The study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets. The study provides analysis of key market dynamics, which influence the adoption of CINV drugs. The report provides a quantitative analysis for the period of 2014-2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry. Extensive analysis of the global market helps understand cancer inducing Nausea and vomiting drugs developed and marketed by the key companies. Competitive intelligence of market players highlights the business practices and trends across various regions.

KEY MARKET SEGMENTS:

By Patient Pool Type: Aloxi, Kytril, Emend, Netupitant-Palonosetron, Others

By Geography: North America, US, Canada, Mexico, Europe, Germany, France, UK, Rest of Europe, Asia-Pacific, China, Japan, Rest of Asia-Pacific, LAMEA, Latin America, Middle East, Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT: GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., Tesaro, Inc.

Additional Details

Publisher : Allied Market Research

Reference : LI 171846

Number of Pages : 70

Report Format : PDF

Publisher Information :

AlliedMarketResearch
Diligent Intelligence - Improved Growth

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022 [Report Updated: 13-01-2017]

- Chapter: 1 INTRODUCTION

- 1.1 Report Description
- 1.2 Key Benefits
- 1.3 Key Market Segments
- 1.4 Research Methodology
 - 1.4.1 Secondary Research
 - 1.4.2 Primary Research
 - 1.4.3 Analyst Tools and Models

- Chapter: 2 EXECUTIVE SUMMARY

- 2.1 CXO Perspective

- Chapter: 3 MARKET OVERVIEW

- 3.1 Market Definition and Scope
- 3.2 Key Findings
 - 3.2.1 Top Impacting Factors
 - 3.2.2 Top Investment Pockets
- 3.3 Porters Five Force Analysis
- 3.4 Drivers
 - 3.4.1 Growing Number of patients undergoing Chemotherapy
 - 3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy
 - 3.4.3 Introduction of novel delivery methods to improve patient compliance.
 - 3.4.4 Advancements in technology to discover new potential drug targets
- 3.5 Restraints
 - 3.5.1 Increasing side effects of CINV drugs
 - 3.5.2 High cost associated with the new drug discovery and in developing regions.
- 3.6 Opportunities
 - 3.6.1 Efficacy of combination therapy is expected to improve.
 - 3.6.2 Improved quality of life for patients with cancer.

- 3.7 Market Trends

- Chapter: 4 CINV MARKET BY PATIENT POOL

4.1 Overview

4.2 Netupitant-Palonosetron FDC

4.2.1 Key market trends

4.2.2 Key growth factors & opportunities

4.2.3 Market size & forecasts

4.3 Aloxi (palonosetron)

4.3.1 Key market trends

4.3.2 Key growth factors & opportunities

4.3.3 Market size & forecasts

4.4 Kytril Generic (Granisetron)

4.4.1 Key market trends

4.4.2 Key growth factors & opportunities

4.4.3 Market size & forecasts

4.5 Emend (aprepitant)

4.5.1 Key market trends

4.5.2 Key growth factors & opportunities

4.5.3 Market size & forecasts

Chapter: 5 CINV MARKET BY GEOGRAPHY

5.1 North America

5.1.1 Key Market Trends

5.1.2 Key Growth Factors and Opportunities

5.1.3 Market Size and Forecast

5.2 Europe

5.2.1 Key Market Trends

5.2.2 Key Growth Factors and Opportunities

5.2.3 Market Size and Forecast

5.3 Asia-Pacific

5.3.1 Key Market Trends

5.3.2 Key Growth Factors and Opportunities

5.3.3 Market Size and Forecast

5.4 Latin America, Middle East and Africa (LAMEA)

5.4.1 Key Market Trends

5.4.2 Key Growth Factors and Opportunities

5.4.3 Market Size and Forecast

Chapter: 6 COMPANY PROFILES

6.1 Helsinn Holding S.A.

6.1.1 Company Overview

6.1.2 Key Strategies and Developments

6.1.3 SWOT Analysis

6.2 Heron Therapeutics, Inc.

6.2.1 Company Overview

6.2.2 Business Performance

6.2.3 Key Strategies and Developments

6.2.4 SWOT Analysis

6.3 Merck & Co., Inc

6.3.1 Company Overview

6.3.2 Business Performance

6.3.3 Key Strategies and Developments

6.3.4 SWOT Analysis

6.4 GlaxoSmithKline plc

6.4.1 Company Overview

6.4.2 Business Performance

6.4.3 Key Strategies and Developments

6.4.4 Key Strategies and Developments

6.4.5 SWOT Analysis

6.5 Cadila Pharmaceuticals Limited

6.5.1 Company Overview

6.5.2 Business Performance

6.5.3 Key Strategies and Developments

6.5.4 Key Strategies and Developments

6.5.5 SWOT Analysis

6.6 Amneal Pharmaceuticals

6.6.1 Company Overview

6.6.2 Business Performance

6.6.3 Key Strategies and Developments

6.6.4 Key Strategies and Developments

6.6.5 SWOT Analysis

6.7 Kyowa Kirin, Inc.

6.7.1 Company Overview

6.7.2 Business Performance

6.7.3 Key Strategies and Developments

6.7.4 Key Strategies and Developments

6.7.5 SWOT Analysis

6.8 Acacia Pharma

6.8.1 Company Overview

6.8.2 Business Performance

6.8.3 Key Strategies and Developments

6.8.4 Key Strategies and Developments

6.8.5 SWOT Analysis

6.9 Insys Therapeutics, Inc

6.9.1 Company Overview

6.9.2 Business Performance

6.9.3 Key Strategies and Developments

6.9.4 Key Strategies and Developments

6.9.5 SWOT Analysis

6.10 Tesaro, Inc.

6.10.1 Company Overview

6.10.2 Business Performance

6.10.3 Key Strategies and Developments

6.10.4 Key Strategies and Developments

6.10.5 SWOT Analysis

*Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.

List of Figures

FIG. 1 TOP IMPACTING FACTORS

FIG. 2 TOP INVESTMENT POCKETS

FIG. 3 PORTERS FIVE FORCES ANALYSIS OF LITHIUM-ION BATTERY MARKET

FIG. 4 WORLD CINV MARKET BY TYPE, 2015(PIE CHART OF GLOBAL NUMBERS BY TYPE)

FIG. 5 WORLD CINV MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)

FIG. 6 NET SALES OF HERON THERAPEUTICS, INC., 2013-2015 (\$MILLION)

FIG. 7 NET SALES OF HERON THERAPEUTICS, INC., BY SEGMENT (%), 2015

FIG. 8 NET SALES OF HERON THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015

FIG. 10 NET SALES OF MERCK & CO., INC, 2013-2015 (\$MILLION)

FIG. 11 NET SALES OF MERCK & CO., INC., BY GEOGRAPHY (%), 2015

FIG. 11 NET SALES OF MERCK & CO., INC., BY SEGMENT (%), 2015

FIG. 12 NET SALES OF GLAXOSMITHKLINE PLC ., 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF GLAXOSMITHKLINE PLC, BY SEGMENT (%), 2015

FIG. 14 NET SALES OF GLAXOSMITHKLINE PLC, BY GEOGRAPHY (%), 2015

FIG. 18 NET SALES OF KYOWA KIRIN, INC., 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF KYOWA KIRIN, INC., BY SEGMENT (%), 2015

FIG. 14 NET SALES OF KYOWA KIRIN, INC., BY GEOGRAPHY (%), 2015

FIG. 22 REVENUE OF INSYS THERAPEUTICS, INC., 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF INSYS THERAPEUTICS, INC., BY SEGMENT (%), 2015

FIG. 14 NET SALES OF INSYS THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015

FIG. 22 REVENUE OF TESARO, INC, 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF TESARO, INC, BY SEGMENT (%), 2015

FIG. 14 NET SALES OF TESARO, INC, BY GEOGRAPHY (%), 2015

List of Tables

TABLE 1 WORLD CINV MARKET BY PATIENT POOL(NETUPITANT-PALONOSETRON FDC) MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 2 WORLD CINV MARKET BY PATIENT POOL(ALOXI) , (\$MILLION), GROWTH (%)2014-2022

TABLE 3 WORLD CINV MARKET BY PATIENT POOL(KYTRIL GENERIC) , (\$MILLION), GROWTH (%)2014-2022

TABLE 4 WORLD CINV MARKET BY PATIENT POOL(EMEND) , (\$MILLION), GROWTH (%)2014-2022

TABLE 5 NORTH AMERICA CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 6 EUROPE CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 7 ASIA CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 8 LAMEA CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 9 HELSINN HOLDING S.A.COMPANY SNAPSHOT
TABLE 9 HELSINN HOLDING S.A.OPERATING SEGMENTS
TABLE 10 HERON THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 11 HERON THERAPEUTICS, INC.OPERATING SEGMENTS
TABLE 12 MERCK & CO., INC. COMPANY SNAPSHOT
TABLE 13 MERCK & CO., INC.OPERATING SEGMENTS
TABLE 14 GLAXOSMITHKLINE PLC COMPANY SNAPSHOT
TABLE 15 GLAXOSMITHKLINE PLC OPERATING SEGMENTS
TABLE 16 CADILA PHARMACEUTICALS LIMITED COMPANY SNAPSHOT
TABLE 17 CADILA PHARMACEUTICALS LIMITED OPERATING SEGMENTS
TABLE 18 AMNEAL PHARMACEUTICALS COMPANY SNAPSHOT
TABLE 19 AMNEAL PHARMACEUTICALS OPERATING SEGMENTS
TABLE 20 KYOWA KIRIN, INC. COMPANY SNAPSHOT
TABLE 21 KYOWA KIRIN, INC. OPERATING SEGMENTS
TABLE 22 ACACIA PHARMA COMPANY SNAPSHOT
TABLE 23 ACACIA PHARMA OPERATING SEGMENTS
TABLE 24 INSYS THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 25 INSYS THERAPEUTICS, INC. OPERATING SEGMENTS
TABLE 26 TESARO, INC. COMPANY SNAPSHOT
TABLE 27 TESARO, INC. OPERATING SEGMENTS

How to Buy...

Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022 [Report Updated: 13-01-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/103426>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$4515** | Single User Price
- \$5910** | Five User License Price
- \$7800** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.